Novartis acquires Nektar's pulmonary business
This article was originally published in Scrip
Novartishas acquired Nektar Therapeutics' pulmonary drug delivery business unit for $115 million in cash. The business, which employs around 140 people, will remain in Nektar's facility in San Carlos, California, and specialises in product formulation and delivery. Novartis hopes to use the acquired business to accelerate its pipeline in such diseases as COPD, asthma and cystic fibrosis. The acquisition will also give Novartis complete control of its joint programme with Nektar for the development of a new formulation of tobramycin for the treatment of lung infections associated with cystic fibrosis. As a result, Novartis will not pay Nektar any future milestones or royalties associated with the development project. The deal, which is expected to close by the end of this year, excludes Nektar's inhalation programmes for insulin, vancomycin, ciprofloxacin and amikacin.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.